An observational study in Osteoarthritis in the Carpometacarpal (CMC) Joint, sponsored by Karolinska Institutet. Completed. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Thumb carpometacarpal (CMC-1) osteoarthritis is a common condition causing pain and disability, particularly among middle-aged and older women. When non-operative treatment fails, surgery is indicated. In Sweden, trapeziectomy (TE), with or without tendon-based adjuncts, is the standard procedure and recommended in the National Care Program introduced in 2022. However, total joint arthroplasty (TJA) has gained popularity because of reports of faster recovery and improved early function, although concerns remain regarding complications, durability, and cost. Comparative studies are therefore needed.
The aim of this study is to compare patient-reported outcomes after dual-mobility TJA versus TE, with or without tendon-based adjuncts, for CMC-1 osteoarthritis using data from the Swedish Hand Surgery Quality Register (HAKIR). To reduce bias in observational data, the study will emulate a hypothetical randomized target trial.
This registry-based cohort study will include adults aged 45 years or older undergoing primary surgery for CMC-1 osteoarthritis. Patients with previous CMC-1 surgery, bilateral procedures, inflammatory joint disease, or extensive missing baseline data will be excluded. Baseline is defined as the date of surgery, and patients will be followed using patient-reported outcome measures collected preoperatively and at 3 and 12 months.
The primary outcome is change in pain on load measured with the HQ-8 questionnaire at 12 months. Secondary outcomes include pain at 3 months, low pain levels at 12 months, other HQ-8 domains, QuickDASH score, patient satisfaction, grip and pinch strength, thumb range of motion, time to reoperation, and postoperative complications.
Potential confounders will be identified using a directed acyclic graph (DAG). Measured confounders include age, sex, surgical centre, calendar year, baseline pain, baseline function, and smoking. Unmeasured factors such as surgeon preference, patient preference, and disease severity not captured in the registry may still cause residual confounding.
Primary analyses will use linear mixed-effects regression to compare adjusted mean pain outcomes between groups at 12 months while accounting for clustering by patient and centre. Secondary outcomes will be analysed using ordinal logistic regression, Cox proportional hazards regression, and logistic regression. Missing data will be handled using multiple imputation, and sensitivity analyses using inverse probability weighting will assess the impact of reoperations and selection bias
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible patients are adults aged ≥45 years with a diagnosis of CMC-1 osteoarthritis (ICD-10 code M18) who have failed non-operative treatment and are scheduled for primary CMC-1 surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
adults aged ≥45 years with a diagnosis of CMC-1 osteoarthritis (ICD-10 code M18) who have failed non-operative treatment and are scheduled for primary CMC-1 surgery.
Exclusion Criteria:
1. Trapeziectomy (TE) with or without tendon adjunct according to routine practice with Flexor Carpi Radialis/Extensor Carpi Radialis Longus/Abductor Pollicis Longus/Palmaris Longus). 2. Total joint thumb base dual mobility arthroplastyDual mobility TJA
Change from baseline to 12 months in pain on load motion measured with the HAKIR questionnaire.
Pain on load motion assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months postoperatively
Change from baseline to 12 months in pain on unloaded motion measured with the HAKIR questionnaire
Pain on unloaded motion assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months after surgery
Change from baseline to 12 months in pain at rest measured with the HQ-8 questionnaire
Pain at rest assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months postoperatively
Change from baseline to 12 months in stiffness measured with the HQ-8 questionnaire
Stiffness assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months postoperatively
Change from baseline to 12 months in weakness measured with the HQ-8 questionnaire
Weakness assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months postoperatively
Change from baseline to 12 months in activities of daily living measured with the HQ-8 questionnaire
Activities of daily living assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.
Time frame: Baseline and 12 months postoperatively
Change from baseline to 12 months in Quick Disabilities of Arm, Shoulder and Hand Questionnaire (Quick DASH)
Upper extremity disability and symptoms assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire. Scores range from 0 to 100, where higher scores indicate greater disability and worse upper extremity function.
Time frame: Baseline and 12 months postoperatively
Change in key pinch strength
kg
Time frame: Baseline and 12 months postoperatively
Change in grip strength
jamar (kg)
Time frame: Baseline and 12 months postoperatively
Change in thumb radial abduction
radial abduction (degrees)
Time frame: Baseline and 12 months postoperatively
Change in thumb plamar abduction
palmar abduction (degrees)
Time frame: From preoperatively to 12 months postoperatively
Time to first reoperation* of the index hand
Time frame: primary horizon: 12 months; secondary: maximum available follow-up
Risk of any (non-reoperation) complication within 12 months
occurrence of any registered postoperative complication of the index hand recorded in HAKIR
Time frame: within 12 months after surgery
No study locations are listed for this record.
Plan to share: Undecided — Data generated and analyzed during this study are stored within HAKIR and are subject to Swedish data protection legislation and the GDPR. Due to legal and ethical restrictions, individual-level participant data cannot be made publicly available. Access to de-identified study data may be granted to qualified researchers upon reasonable request and subject to approval by the Swedish Ethical Review Authority and the HAKIR steering committee. Access to the statistical code will be granted after reasonable request.
No publications or documents are linked to this record.
Ran from Jan 2011 to primary completion in Dec 2025, 179 months.
Of 146 non-industry observational studies under Osteoarthritis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 97. This study's 179 months is above that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.